4 August 2023
HealthBeacon plc
Notice of Annual General Meeting
Dublin, HealthBeacon plc ("HealthBeacon" or "the Company"), today announces that the Letter from the Chairman, Notice of Annual General Meeting and Form of Proxy have been issued to shareholders for the upcoming Annual General Meeting for year ended 31 December 2022.
The Annual General Meeting will be held on 31 August 2023 at 8am in The Alex Hotel Dublin, 41-47 Fenian Street, Dublin 2, D02 H678.
Copies of the Annual Report, Chairman's Letter, Notice AGM, Form of Proxy and Annual Report are available online at https://healthbeacon.com/2023-agm/.
For further information, contact:
HealthBeacon plc
Unit 20
Naas Road Business Park
Muirfield Drive
Naas Road
Dublin 12
D12 WD85
T: +353 1 4508480
E: company.secretary@healthbeacon.com
Goodbody (Euronext Listing Sponsor and Broker):
David Kearney +353 (1) 667 0420
Stephen Kane
About HealthBeacon:
Headquartered in Dublin, HealthBeacon is an Irish digital therapeutics company that
develops smart tools for managing medications for patients in the home.
The HealthBeacon Injection Care Management System tracks adherence and persistence with medication schedules through the provision of medication management reminders, safe and sustainable sharps disposal devices, educational tools, and artificial intelligence (AI) driven data analytics.
Peer reviewed evidence supports a 19% improvement in therapy persistence by patients and up to 26% improvement in adherence to therapy, which improves clinical outcomes and significantly improves efficiency in health systems.
The Company has expanded its offering to growth management with the launch of its
integrated Smart Scale and oral adherence with the launch of HB Wave which integrates
with its existing technology.
The Company operates across Europe, North America and the United Kingdom and employs more than 70 people and has obtained more than 30 design and utility patents.
The Company's mission is to become the world's leading digital therapeutics platform for patients managing medications in the home.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.